President Donald Trump announced Friday that all 50 states will join a Medicaid program providing Most Favored Nation pricing to some drugs.
The plan, dubbed the Medicaid “GENEROUS” model, is set to bring net drug prices down to levels paid in certain other countries.
Trump administration claims Medicaid will save billions on prescription drug costs. In May, the White House estimated Trump’s drug company deals could save $529 billion over 10 years.
How the model works
The administration signed an executive order last year instituting a “Most Favored Nations” policy, where the U.S. would pay the same price for medications as the nation paying the lowest price anywhere.
Under the plan, every state will be able to use savings “to invest in other healthcare improvements or something else,” Trump said.
The administration’s defenders
The administration has pushed back hard against criticism. Kush Desai, a White House spokesman, defended the administration’s lack of disclosure by citing drug deals under the Inflation Reduction Act that also omitted commercially sensitive information.
He said critics should be regarded as “an idiot or partisan hack.”
Experts push back
Experts say savings are unclear since deal contents are not publicly disclosed. Kathy Hempstead, a senior policy adviser at the Robert Wood Johnson Foundation, said there is significant pressure on the administration to provide more granular data to justify cost-savings claims.
Hempstead warned that Congress would have trouble codifying MFN arrangements without knowing what’s in the deals.
JD Hayworth, a former Republican congressman and spokesperson for the Pharmaceutical Reform Alliance, said the announcement shows “meaningful progress, but that progress remains incomplete,” adding that millions of Americans not enrolled in government healthcare want lower drug prices.
Drug prices can depend on competition, insurance coverage, and whether patients get coverage through work, the individual market, Medicaid, or Medicare.
What we do not know
The administration has released few details of the deals. Critics say that makes it hard to judge the claims.
The savings are claimed, the model is named, and the states are on board. What remains unknown is whether the deals will actually produce the projected savings.
Comparing the two sides
| Side | Position | Key claim |
|---|---|---|
| Administration | Defends deal secrecy | Saves $529 billion over 10 years |
| Critics | Want more transparency | Deal terms not publicly disclosed |
The stakes
The savings estimates are large, but the administration has so far released few details of the deals. Without those details, it is impossible to judge whether the plan will deliver what it promises.
The administration’s position rests on three things:
- The “GENEROUS” model applies only to Medicaid.
- The White House has estimated $529 billion in savings over 10 years.
- All 50 states have agreed to join.
The savings are claimed, the model is named, and the states are on board. What remains unknown is whether the deals will actually produce the projected savings.
Where the paper stands
The paper backs none of the parties in this story and instead backs citizens and states keeping decisions about their own health care, rather than a national plan that could centralize authority over drug pricing. The paper is AGAINST agencies that write their own authority and mandates on private life.
The administration has signed an executive order setting a national price for drugs based on what other nations pay, and the White House claims the plan will cut $529 billion from Medicaid spending over 10 years. But the administration has released few details of the deals, and critics say without those details it is impossible to judge whether the plan will deliver what it promises. The paper believes citizens and states should keep decision-making power rather than letting one national office gather control over drug prices.
The administration’s defenders cite drug deals under the Inflation Reduction Act that also omitted commercially sensitive information. The paper believes cost-savings claims should be publicly warranted rather than defended through secrecy.
Source material: “Trump announces all 50 states joining Medicaid drug pricing model,” PBS.
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.